Lung cancer drug patterns revealed in australian study
NCT ID NCT07213076
First seen Oct 31, 2025 · Last updated Jun 11, 2026 · Updated 27 times
Summary
This study reviewed medical records of 350 Australian patients with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). Researchers looked at how long patients stayed on the drug osimertinib when it was given as their first or second treatment, and how well it worked. The goal was to understand real-world treatment patterns and outcomes, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Melbourne, Victoria, 3000, Australia
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.